Not Yet Recruiting OBSERVATIONAL NCT06426758

Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation

The Morbidity of Graves' Disease and Recurrence Rate of Hyperthyroidism Due to Epstein-Barr Virus Lytic Reactivation

Sponsor: National Natural Science Foundation of China

Conditions Epstein-Barr Virus Graves Disease Graves' Disease in Remission

Updated 3 times since 2024 Last updated: May 19, 2024 Started: May 30, 2024 Primary completion: Sep 1, 2026 Completion: Sep 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06426758, this observational or N/A phase trial focuses on Epstein-Barr Virus and Graves Disease and remains actively recruiting participants. Sponsored by National Natural Science Foundation of China, it has been updated 3 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting

First recorded

May 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Natural Science Foundation of China
Xiao-Ming Mao

Data source: Nanjing Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanjing, China